Intellia Therapeutics, Inc.
NTLA
$9.52
-$2.80-22.73%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 14.99% | -13.37% | 59.55% | -16.77% | -13.33% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.99% | -13.37% | 59.55% | -16.77% | -13.33% |
| Cost of Revenue | -1.32% | -0.15% | 4.01% | 4.35% | 6.33% |
| Gross Profit | 3.25% | -1.60% | 1.04% | -7.27% | -9.26% |
| SG&A Expenses | 0.45% | 14.47% | 19.83% | 22.52% | 30.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.90% | 2.93% | 7.36% | 8.10% | 11.12% |
| Operating Income | 2.29% | -4.59% | -3.68% | -10.76% | -13.95% |
| Income Before Tax | 5.62% | -8.32% | -7.86% | -12.94% | -12.21% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 5.62% | -8.32% | -7.86% | -12.94% | -12.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.62% | -8.32% | -7.86% | -12.94% | -12.21% |
| EBIT | 2.29% | -4.59% | -3.68% | -10.76% | -13.95% |
| EBITDA | 2.39% | -4.51% | -3.49% | -10.60% | -13.83% |
| EPS Basic | 14.42% | 2.57% | 3.09% | -1.74% | -0.33% |
| Normalized Basic EPS | 11.24% | 6.89% | 9.24% | 2.71% | 1.61% |
| EPS Diluted | 14.42% | 2.57% | 3.09% | -1.74% | -0.33% |
| Normalized Diluted EPS | 11.24% | 6.89% | 9.24% | 2.71% | 1.61% |
| Average Basic Shares Outstanding | 10.36% | 11.17% | 11.34% | 11.02% | 11.51% |
| Average Diluted Shares Outstanding | 10.36% | 11.17% | 11.34% | 11.02% | 11.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |